



New Perspectives on the Measurement of Free Light Chains in the Different Matrices: Serum, Urine, and Cerebrospinal Fluid

Guest Editor:

Dr. Massimo Pieri

1. Department of Experimental Medicine, University of Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy
2. Department of Medicinal Laboratory, Tor Vergata University Hospital, Rome, Italy

Deadline for manuscript submissions:
closed (30 April 2024)

Message from the Guest Editor

The determination of free light-chains (S-FLCs) in serum has been a turning point in the diagnosis, prognosis, and monitoring of monoclonal gammopathies of undetermined significance (MGUS), multiple myeloma (MM), and light-chain amyloidosis (AL). The method, established in the 2000s, quantifies serum-FLC using polyclonal antibodies to identify the presence and pattern of multiple myelomas in patients; meanwhile, the assays are nowadays more often based on monoclonal antibodies. Since the FLC are the isoforms, kappa (κ) and lambda (λ), of the light chains of immunoglobulins that circulate unbound in the serum, in order to facilitate the interpretation, the results of their quantities will be accompanied by a ratio. The calculated value of κ/λ free chains (FLC) relative to the reference intervals may indicate the presence of plasma cell dyscrasias in the patient, such as multiple myeloma or AL amyloidosis.

The Special Issue will also address the possible benefits of using the new generation FLC tests and new experimental approaches used in laboratories.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Omar Cauli

Frailty and Cognitive Impairment
—FROG Research Group,
University of Valencia, 46010
Valencia, Spain

Message from the Editor-in-Chief

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental)

Contact Us

Diseases Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/diseases
diseases@mdpi.com
X@Diseases_MDPI